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ARTICLE
The Translational Science Benefits Model: A New
Framework for Assessing the Health and Societal Benefits
of Clinical and Translational Sciences
Douglas A. Luke1,∗, Cathy C. Sarli2, Amy M. Suiter2, Bobbi J. Carothers1, Todd B. Combs1, Jae L. Allen3, Courtney E. Beers3
and Bradley A. Evanoff4
We report the development of the Translational Science Benefits Model (TSBM), a framework designed to support institutional
assessment of clinical and translational research outcomes to measure clinical and community health impacts beyond biblio-
metric measures. The TSBM includes 30 specific and potentially measurable indicators that reflect benefits that accrue from
clinical and translational science research such as products, system characteristics, or activities. Development of the TSBM
was based on literature review, a modified Delphi method, and in-house expert panel feedback. Three case studies illustrate
the feasibility and face validity of the TSBM for identification of clinical and community health impacts that result from trans-
lational science activities. Future plans for the TSBM include further pilot testing and a resource library that will be freely
available for evaluators, translational scientists, and academic institutions who wish to implement the TSBM framework in
their own evaluation efforts.
Clin Transl Sci (2018) 11, 77–84; doi:10.1111/cts.12495; published online on 8 September 2017.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Most current knowledge on the topic of the value of clin-
ical and translational research focuses on productivity mea-
sures such as bibliometrics and grant funding.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ This study addresses the question of how to mea-
sure broader impacts of research, including lives saved,
improvements to health, and cost savings.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✔ This study presents a framework that can be used to
assess or evaluate these processes and outcomes.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE
✔ By emphasizing the importance of the long-term
impacts of clinical and translational science, we can bet-
ter understand its value to society and securing funding in
an ever-increasingly competitive budgetary environment.
One reason governments fund research is for the value it
provides to society.1 Therefore, it is important to demon-
strate what that value is. This can be challenging. Tradi-
tional approaches to assess the value of research rely heav-
ily on quantitative measures of scientific productivity, such
as grant submissions, grant funding, publications, and cita-
tions. This focus on bibliometrics emphasizes the outcomes
that are of primary interest to scientists themselves, and over-
looks broader benefits to human health and society, such
as lives saved, improvements to health, or cost savings. In
an era of shrinking research funding and an emphasis to
speed translation of research to practice and demonstrate
real-world outcomes that accrue from science, it becomes
even more important to develop new approaches for doc-
umenting the many ways that research benefits society at
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large. While this broader impact may be hard to measure, it
is critical for understanding the total value our society gains
from its investment in the scientific enterprise.2
Following the science into the community is a chal-
lenge facing institutions with a Clinical and Translational
Science Award (CTSA). CTSAs are funded by the National
Center for Advancing Translational Sciences (NCATS). The
NCATS goals focus on practices such as training of trans-
lational science workforce, increasing the quality and effi-
ciency of translational research, and engaging communities
in the translational process.3 The NCATS’ goals are consis-
tent with Woolf’s two-component definition of translational
science: i) “the bench-to-bedside enterprise of harnessing
knowledge from basic sciences to produce new drugs,
devices, and treatment options for patients” and; ii) the
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translation of research into practice; that is, “ensuring that
new treatments and research knowledge actually reach the
patients or populations for whom they are intended and are
implemented correctly.”4 Thus, translational research is fun-
damentally concerned with how research benefits patients,
communities, and populations.
In 2013, the Institute of Medicine (IOM) released an eval-
uation report on the CTSA program. The report recognized
the importance of the CTSA mission for accelerating the
translation of basic and clinical science to benefit individ-
ual patients and communities. The report also emphasized
evaluation and assessment by recommending that NCATS
“formalize and standardize the evaluation processes for indi-
vidual CTSAs and the CTSA Program.”5 Responding to this,
NCATS launched the Common Metrics Initiative in Decem-
ber 2015.6 The Initiative aims to develop and implement a
set of Common Metrics that will be applied across CTSA
Hubs and considered in evaluation of the impact of the
CTSA Program as a whole. These metrics cover important
measureable objectives focusing on the research process
(e.g., median Institutional Review Board (IRB) review dura-
tion), career development (e.g., retention of scholars and
trainees in clinical and translational research fields, diver-
sity of scholars and trainees), and scientific productivity (e.g.,
pilot awards that yielded publications and/or subsequent
funding).7–9
These common metrics capture important aspects of the
functioning of CTSA programs but are less useful in eval-
uating longer-term impacts of translational science. New
scientific discoveries from CTSAs are translated into clinical
applications, healthcare guidelines, therapeutic techniques,
medical devices, community interventions, and other
outcomes that benefit societal health. These beneficial out-
comes are typically not captured by most scientific impact
assessment systems,10 which tend to focus on bibliometric
measures of scientific productivity.11 These broader soci-
etal and community benefits are difficult to measure for
reasons such as the time lag between research discovery
and translational applications and difficulty in establishing
a direct connection from a specific research output to a
subsequent impact. Scientists themselves are often not
aware of the impact of their research, lack academic incen-
tives for translation of research to practice, and are not
typically trained to communicate their research beyond the
scientific community. This type of impact measurement is
critical for understanding the total value society gains from
its investment in the CTSA awards.
A more systematic method is needed to measure trans-
lational scientific endeavors that result in health and social
benefits. To address this need, the Institute for Clinical
and Translational Sciences (ICTS) Tracking and Evaluation
Team (T&E Team) at Washington University in St. Louis
developed a new framework for measuring the impact of
a large-scale translational science initiative: the Transla-
tional Science Benefits Model (TSBM). The development of
the framework was inspired by the desire to look beyond
“science begets science” counts of the medical enterprise to
identify examples of real-world clinical and community health
impacts that result from translational science activities. The
TSBM is informed by recent efforts to develop translational
research frameworks and logic models12,13 and is designed
to support institutional assessment of clinical and transla-
tional research outcomes. It also can guide future evalua-
tion research designed to identify the most important orga-
nizational factors associated with these health and social
outcomes.
In this article we i) present the rationale for assessing ben-
efits of translational science beyond scientific productivity; ii)
describe the development of the TSBM; and iii) illustrate the
application of the TSBM with three case studies.
METHODS
The TSBM is a conceptual framework development study pri-
marily based on a comprehensive literature review, a modi-
fied Delphi technique,14 and in-house expert panel feedback.
This project was conducted by the ICTS T&E Team (CTSA
Award UL1 TR000448).
We identified models and frameworks for assessing sci-
entific activities, outcomes, and impact through a review
of the literature, and compiled a list of domains and indi-
cators that represented stages of clinical and translational
science activity. Specific models and frameworks that were
reviewed include the Process Marker Model,15 the Trans-
lational Research Impact Scale,12 the Research Impact
Framework,16 the Payback Model,17 the Snowball Metrics,18
and the Becker Model, previously developed at Washington
University.13 The models and frameworks were abstracted
and summarized by the authors and members of the ICTS
T&E Team.
Indicators of translational science outcomes were then
selected from and compared across three sources: the
Becker Model for Assessment of Research Impact,13 the
Translational Research Impact Scale,12 and the Snowball
Metrics.18 These sources were selected because they con-
tained indicators that were specific to clinical and trans-
lational science research outcomes, as well as scientific
outputs and outcomes. They were combined into a sin-
gle list of 240 indicators (Supplemental Data). A modified
Delphi Method19 was used whereby the ICTS T&E team
acted as an expert panel and took several passes through
the data to i) remove duplicate items, ii) sort into loose
conceptual categories, iii) remove confusing and poorly
worded items, and iv) retain items that were the most con-
ceptually clear and most commonly found in the scien-
tific assessment literature. Disagreements among the T&E
team were resolved through discussion until consensus was
reached.
Given the assessment and evaluation goals of this project,
we also developed a logic model for translational science
outcomes, based on accepted evaluation best practices.20,21
This logic model emphasized the translational activities nec-
essary to connect research results and evidence to improved
health outcomes.22,23
The new logic model and translational science bene-
fits indicators were then vetted using an in-house expert
review with the ICTS Director and the Program Director for
the ICTS Dissemination and Implementation Research Core.
Suggestions were implemented in a revised model, then
presented to the members of the ICTS External Advisory
Clinical and Translational Science
Translational Science Benefits Model
Luke et al.
79
Board during an annual meeting. To reflect the focus on clin-
ical and translational benefits, the model was named the
Translational Science Benefits Model.
RESULTS
Logic model and benefit domains
The first step in the development of the TSBM was creating
a logic model that links scientific activities and outcomes to
downstream public health and social benefits (Figure 1). In
this model, scientific activities are supported by a variety of
financial, infrastructure, human, and knowledge resources.
This scientific activity results in a variety of scientific out-
puts (e.g., results, data, and publications) that in turn are
delivered in a variety of translational science settings and
products.
Although the TSBM is consistent with broader models of
scientific activity,16,24,25 it was designed to be specifically
applicable to clinical and translational research. To that end,
two translational phases are highlighted in the model. First,
the raw results of scientific activities are translated for a pri-
marily scientific audience. This captures the traditional flow
of science into scientific journals, conferences, and other
venues where scientific results become visible and primar-
ily influence other scientists.
The second translational phase is the process of dis-
semination and implementation where scientific findings that
are relevant for new treatments, programs, and policies are
tailored and disseminated to a broader audience of clinicians,
hospital administrators, policymakers, health advocates, and
funders.
The primary contribution of the TSBM is to identify and
define the areas where clinical and translational science
provides health and societal benefits. We suggest that
these benefits fall into four categories. i) Clinical and Med-
ical Benefits: Adoption and implementation of new tools
and procedures in clinical settings as a result of clinical
and translational research. ii) Community and Public Health
Benefits: Enhancement of healthcare or community and pop-
ulation well-being as a result of clinical and translational
research. iii) Economic Benefits: Economic, commercial, or
financial improvements that result from clinical and transla-
tional research. iv) Policy and Legislative Benefits: Involve-
ment with the policy-making process or formal adoption into
organizational or public policies, legislation, or governmental
standards based on clinical and translational research. This
definition is broad enough to include both “big P” policies
(formal laws or rules enacted by governmental bodies) and
“small P” policies (organizational guidelines, internal agency
decisions).26
More specifically, the TSBM suggests that certain results
and discoveries made by clinical and translational scien-
tists get translated and disseminated beyond a purely sci-
entific audience. The fruits of this science may lead to
advances and innovations in clinical settings; changes to
health systems and health promotion activities that lead
Figure 1 Translational Science Benefits Logic Model.
www.cts-journal.com
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Figure 2 Translational Science Benefits Model Domains and Indicators.
to health improvements in communities and populations;
development of commercial products and other advances
that have positive economic consequence; and finally, imple-
mentation of evidence-based policies and regulations that all
serve to reduce disease and disability, and promote public
health. Figure 2 lists the four benefits domains with their indi-
cators. Each of the domains includes two or three categories
that group the indicators into similar sets. For example, five
of the Clinical & Medical Benefits indicators are all types of
tools and products.
The final TSBM includes 30 indicators and their defini-
tions (Appendix). The definitions are relatively straightfor-
ward, but the National Library of Medicine Medical Subject
Headings (MeSH) was also used to enhance consistency
across definitions.27 These indicators reflect the wide variety
of benefits that accrue from clinical and translational science
research while including specific things or products (e.g.,
new biomedical technology used in a clinical setting), system
characteristics or activities (e.g., accessibility of healthcare
services), or effects (e.g., improved life expectancy). The indi-
cators are specific, observable, and are each at least poten-
tially measurable. That is, they are defined in such a way that
they can lead to a measurable metric, and can be linked to
institutional SMART objectives (i.e., specific, measureable,
achievable, relevant, time-bound).28 For example, if a trans-
lational research project leads to development of a new elec-
tronic technology for healthcare providers to use in the clin-
ical setting, this benefit would be captured by the Software
Technologies indicator within the Clinical and Medical Ben-
efits domain. Conversely, if a research program resulted in
updated evidence-based guidelines by a public health body
such as the Centers for Disease Control, that benefit would
be captured by the Public Health Practices indicator in the
Community and Public Health Benefits domain. In this sense,
the TSBM indicators represent new or improved benefits that
accrue from clinical and translational science research.
Case studies
To provide supporting information regarding the feasibility
and face validity of the TSBM, we conducted a set of case
studies demonstrating the application of the TSBM to clin-
ical and translational science research projects that were
led by Washington University ICTS members.29 To deter-
mine potential projects for case studies, the ICTS leadership
identified bench and clinical investigators who had received
ICTS core services or funding from 2007–2012. Studies were
selected by evaluating ICTS core usage, publication, grant
application, and award data while considering anecdotal
information such as success stories highlighted in institu-
tional, regional or national media and feedback to ICTS lead-
ership about research findings. We do not expect that any
single clinical research study would lead to all the benefits
described in the TSBM. However, this type of research often
leads to benefits in more than one of the four TSBM domains
(e.g., a clinical study producing a new diagnostic tool could
very well lead to clinical benefits as well as economic ben-
efits). To that end, the case study development emphasized
clinical research that could have benefits in more than one
domain.
Ten research studies were identified as possibilities to use
for preliminary testing of the new model. Of those, three
studies whose findings resulted in potential scientific and
translational benefits were ultimately selected for case study
development. These three studies were selected because
i) they represented at least one basic/bench science study
and one clinical research study, ii) they represented transla-
tional research in different stages, iii) they illustrated a vari-
ety of indicators from the four TSBM domains, and iv) their
investigators were willing to participate in the development of
the TSBM. These case studies represent preliminary testing
results for illustrative purposes and identifying challenges for
the future development of an assessment system based on
the TSBM.
Clinical and Translational Science
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Table 1 Translational Science Benefits Model observed indicators for the
Diagnosis of Kidney Cancer study
Benefit TSBM Domain TSBM Indicator












CASE STUDY #1: SPECIFIC NON-INVASIVE DIAGNOSIS
OF KIDNEY CANCER
Study description
The Specific Non-Invasive Diagnosis of Kidney Cancer
study explores urine biomarkers for detecting kidney cancer.
Jeremiah J. Morrissey, PhD, received ICTS pilot funding in
2009 and 2011 to study urine biomarkers. The goals of this
study were to establish the ability of markers in urine and
blood to diagnose kidney cancer, differentiate kidney can-
cers from other cancers of the urinary tract or common non-
cancerous kidney diseases, and monitor for recurrence and
the effectiveness of chemotherapy in patients withmetastatic
disease.
Dr. Morrissey reported that the findings from the study val-
idated the clinical utility of the urine biomarkers for screening
of renal cell carcinoma.45,46 His team is currently investigating
several noninvasive screening test applications for detecting
kidney cancer at early, more treatable stages before patients
have symptoms. The study is noteworthy as there is cur-
rently no method for early detection of kidney cancer, nor
are there methods of surveillance of recurrence or testing of
response to chemotherapy. These challenges are important
to overcome because kidney cancer is difficult to treat unless
caught early and is known to be resistant to chemotherapy
and radiation.
TSBM indicators
Early benefits of the Kidney Cancer study have been
observed in two of the four TSBM domains over the past few
years (Table 1). A patent for methods to detect and diagnose
renal cancer using biomarkers has been granted and is avail-
able for licensing.30 Studies for the development of screen-
ing assays for early detection of kidney cancer are in pro-
cess. Development of promising and affordable applications
for early detection is expected to provide several benefits:
reduced mortality rate, less invasive treatment, and preser-
vation of renal function. Early detection methods for kidney
cancer can be incorporated into everyday medical practice
and provide significant benefits to societal health.
CASE STUDY #2: DIAGNOSTIC PROCEDURES FOR
CREUTZFELDT–JAKOB DISEASE (CJD)
Study description
The Diagnostic Procedures for Creutzfeldt–Jakob Disease
(CJD) study explores diffusion tensor imaging (DTI) as an
early biomarker for diagnostic purposes. CJD is a rapidly
progressive neurodegenerative disease (RPD) with diagnosis
often made at autopsy. Beau M. Ances, MD, PhD, MSc, was
Table 2 Translational Science Benefits Model observed indicators for the
Creutzfeldt-Jakob Disease study
Benefit TSBM Domain TSBM Indicator
Preliminary identification
of clinical and diagnostic





Saves patients from need
for brain biopsy;





Recognition from the CJD






















Change in Texas State





awarded ICTS pilot funding in 2009 for research to study CJD
and DTI. The goal of this study was to identify early changes
in the brain structure due to CJD that may allow for early
intervention. The research led to hosting of the Evaluation of
CJD & other Rapidly Progressive Dementias conference in
St. Louis, a CJD Foundation Family Workshop in 2012, and
several journal articles.31,32
The CJD research was important because it resulted in
new preliminary diagnostic procedures and clinical practices
and increased the community awareness of a rare and devas-
tating disease. The results have led to procedures for earlier
and less invasive diagnosis of CJD, benefiting both patients
and healthcare workers.
TSBM indicators
Benefits of the CJD study represent all four TSBM domains
(Table 2). Under the Clinical and Medical Benefits domain,
the CJD study has led to a new Barnes-Jewish Hospital pol-
icy for treatment of CJD patients and resulted in preliminary
identification of clinical and diagnostic tests such as MRI and
lumbar puncture to distinguish CJD from other RPDs. For
the Community and Public Health Benefits domain, the CJD
study saves patients from the need for brain biopsy, reduces
risks to patients and healthcare workers, and received recog-
nition for the CJD Foundation as a source of knowledge
and assistance for patients and families, which has led to
increased referral and volume of CJD patients to Washington
University. For the Economic Benefits domain, fewer tests are
being ordered for patients and the length of hospital stay has
decreased. For the Policy and Legislative Benefits domain,
results of the CJD study have been communicated to State
Health Boards with revisions in policies leading to an increase
www.cts-journal.com
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in reporting of CJD cases in Texas. These outcomes reflect
tangible real-world health impacts.
CASE STUDY #3: THE CONTRACEPTIVE CHOICE
PROJECT
Study description
The Contraceptive CHOICE Project is a large clinical trial
research study with the goal of increasing uptake of long-
acting reversible contraception and decreasing unintended
pregnancy in the St. Louis area. Jeffrey Peipert, MD, PhD, a
Principal Investigator for the Contraceptive Choice Project,
utilized support from the ICTS from 2007 to 2012 for KL2
scholars, TL1 trainees, and consultations with ICTS related
to this project. The project involved nearly 10,000 women
from the area along with community partners and private
providers.33 Providing no-cost contraception to teens in the
CHOICE Project dramatically reduced the teen pregnancy
and abortion rate for the St. Louis area. Of the 1,404 teens
in the project, 72% chose a Long-Acting Reversible Contra-
ceptive (LARC) method. The teen pregnancy rate was 34.0
per 1,000 teens compared to the national average of 158.5
per 1,000 teens. Additionally, the abortion rate for teens in
the CHOICE project was 9.7 per 1,000 teens compared to the
national average of 41.5 per 1,000 teens.34 Reduction of teen
pregnancy rates is among the six identified CDC Winnable
Battles for 2010–2015.35
The CHOICE Project is important from a clinical and trans-
lational aspect, as it represents a fundamental shift in the use
of contraceptive methods and garnered significant attention
from the community and media. The project demonstrated
that removing barriers to highly effective contraceptive meth-
ods such as IUDs and implants reduces unintended pregnan-
cies and the need for abortions.
TSBM indicators
Benefits of the CHOICE Project represent three of the four
TSBM domains (Table 3). As a Clinical and Medical Ben-
efit, CHOICE was cited in two professional pediatric clini-
cal guidelines: the American Academy of Pediatrics Policy
Statement, Contraception for Adolescents, 2014, and the
American College of Obstetricians and Gynecologists Prac-
tice Bulletin, Long-Acting Reversible Contraception: Implants
and Intrauterine Devices, 2013.36,37
Community and public health benefits of the CHOICE
Project are seen in three different ways: a new women’s
health community center (C3) based on the Contraceptive
Choice Project model of care has been established,38 project
investigators currently provide clinical training for members
of the community, and the recommendations from the study
are currently being tested in Australia (The Australian Con-
traceptive Choice Project, ACCoRd).39 The clinical trial itself
dramatically reduced unintended pregnancy and abortion
rates for the entire St. Louis region. Finally, the CHOICE
project has also shown potential policy impacts since it was
cited in an amicus brief submitted to the U.S. Supreme
Court in 2014 by the Guttmacher Institute.40 The CHOICE
project was cited as evidence of how effective contraception
reduces the need for abortion, potentially preventing more
than half of abortions performed annually.
Table 3 Translational Science BenefitsModel observed indicators for the Con-
traceptive CHOICE Project
Benefit TSBM Domain TSBM Indicator








































THE CASE STUDIES AND THE STAGES OF
TRANSLATIONAL RESEARCH
It is important to clarify that the case studies explored
here were in different phases and represent different stages
of translational research. Each of these points affects the
analysis and classification of translational science benefits.
Figure 3 places the case studies on a continuum of trans-
lational research.41 Cases 1 (Kidney) and 2 (CJD) concerned
identification of problems and development of interventions
(T0-T1). Case 2 also developed guidelines for early detec-
tion of CJD and led to policy and process changes through
implementation of the new guidelines (T2-T3). Finally, Case
3 (CHOICE) began at a later translational research stage by
testing an evidence-based intervention (T3) and evaluating
its effectiveness in the real world (T4).
DISCUSSION
In this article we presented a new framework for identifying
and describing the many benefits that can derive from trans-
lational and clinical science. The TSBM is based on past work
from the field of scientific evaluation, but focuses on trans-
lational science and is designed to support feasible evalua-
tion metrics and processes. As the three case studies sug-
gest, successful clinical research that is primarily designed to
answer important biological, medical, or healthcare delivery
questions can have long-term effects (Table 4). In just a few
years after initial funding and support from CTSA resources,
these studies resulted in clinical, community, economic, and
policy benefits that analysis of publication, grant application,
or survey data would not have revealed. Furthermore, placing
these studies in the larger framework of the stages of trans-
lational research suggests that as a research program pro-
gresses through these stages, benefits will likely increase,
and benefits from research at later stages may be more
Clinical and Translational Science
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Figure 3 Case Studies and the Stages of Translational Research.
Table 4 Summary of Translational Science Benefits Model indicators for three
case studies














Community and Public Health Benefits
















readily achievable or apparent than those at earlier ones, i.e.,
the two studies addressing T2-T4 research garnered more
tangible benefits.
Measuring the benefit of research is an emerging
methodology and requires innovative tools to supplement
peer-review and bibliometrics.42 Measuring benefits that fall
outside of scientific productivity metrics have their own set
of challenges. A distinct community devoted to evaluation
of research benefits with its own series of conferences or
journals does not currently exist.43 Although some bene-
fits such as formal clinical guidelines or patents have exist-
ing administrative methods for tracking, many others do not
(e.g., expert testimony). Finally, even with new health and
societal benefit metrics available, we are still confronted with
the basic evaluation challenges of how to demonstrate direct
associations between research funding, scientific outcomes,
and subsequent downstream social and health benefits.44
Implementing formal evaluation systems based on the TSBM
requires new partnerships between clinical scientists, aca-
demic administration, funders, and many relevant stakehold-
ers (e.g., practitioners, policy makers).
The TSBM complements other efforts to study the pro-
cesses and outcomes of research funding. Universities
and research organizations are striving to translate benefits
beyond academia to demonstrate impactful research out-
comes and contributions towards the mission of the univer-
sity. For example, the American Association of Medical Col-
leges (AAMC), with the support of RAND Europe, launched a
research evaluation initiative to help medical schools intro-
duce more comprehensive approaches to evaluating the
value of research and provide a fuller picture in which
research benefits institutions, patients, and communities.47
The three areas of focus are clinical outcomes improvement
research, health equity research, and basic research.
Funding agencies are also focusing on metrics that tran-
scend traditional measures of reporting on productivity (e.g.,
citations, journal impact factor score) towards outcomes
such as clinical applications, influence on public policy, or
community engagement endeavors. One recent effort is the
Science Impact Framework developed by the Centers for
Disease Control and Prevention (CDC), employing indica-
tors to measure impact towards health outcomes.48 Agen-
cies such as the National Institute of Environmental Health
Sciences (NIEHS) have implemented strong evaluation pro-
grams that emphasize reporting of qualitative-based out-
comes and produced a manual designed to demonstrate
achievements in environmental public health.49
FUTURE PLANS
The long-term goal for the TSBM project is to develop the
model as an evaluation system for clinical and translational
research to supplement assessment systems that use tradi-
tional bibliometric methods. The activities reported here rep-
resent the first part of this longer-term project. Two more
steps are planned that will build off the developed TSBM
logic model and indicators. First, a TSBM resource library
is being developed that will provide guidance on how to
use each indicator. This is being developed by ICTS and
the Becker Medical Library at Washington University, and
will be freely available for clinical and translational scientific
institutions (CTSA Hubs and others). Second, pilot-testing
of specific metrics that can be used to measure each of
the TSBM indicators will be conducted. This will provide
important guidance for evaluators, translational scientists,
and academic institutions who wish to implement the TSBM
in their own evaluation efforts.
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